Polycystic ovary syndrome is associated with nonalcoholic steatohepatitis in women of reproductive age

Stephanie S. Maldonado, Joshua Grab, Connie W. Wang, Heather Huddleston, Marcelle Cedars, Monika Sarkar – 20 July 2022 – Polycystic ovary syndrome (PCOS) occurs in approximately 10% of all reproductive‐age women, with over 50% of these patients having imaging‐confirmed nonalcoholic fatty liver disease (NAFLD). Whether PCOS increases the risk for more clinically relevant disease, such as nonalcoholic steatohepatitis (NASH), is unclear. Such findings are relevant to prognosticating risk of progressive liver disease in the growing population of young adults with NAFLD.

Speech patterns and enunciation for encephalopathy determination—A prospective study of hepatic encephalopathy

Andrew M. Moon, Hannah P. Kim, Sarah Cook, Renee T. Blanchard, Katarina L. Haley, Adam Jacks, Jennifer S. Shafer, Michael W. Fried – 20 July 2022 – Hepatic encephalopathy (HE) is a complication of cirrhosis that benefits from early diagnosis and treatment. We aimed to characterize speech patterns of individuals with HE to investigate its potential to diagnose and monitor HE. This was a single‐center prospective cohort study that included participants with cirrhosis with HE (minimal HE [MHE] and overt HE [OHE]), cirrhosis without HE, and participants without liver disease.

Co‐regulation of hepatic steatosis by ferritinophagy and unsaturated fatty acid supply

Ning Li, Yilie Liao, Haipeng Huang, Suneng Fu – 20 July 2022 – Both iron overload and iron deficiency have been reported in obesity and metabolic syndromes. Due to the presence of multiple intracellular iron pools and the dynamic nature of iron mobilization and use, the actual status and contribution of free and metabolically active iron toward metabolic syndrome remain to be established. The discovery of nuclear receptor coactivator 4 (NCOA4) as a ferritinophagy receptor provides an opening to address the connection between iron and metabolic diseases.

Inhibition of CBP/β‐catenin signaling ameliorated fibrosis in cholestatic liver disease

Masamichi Kimura, Koji Nishikawa, Yosuke Osawa, Jun Imamura, Kenzaburo Yamaji, Kenichi Harada, Hiroshi Yatsuhashi, Kazumoto Murata, Kouichi Miura, Atsushi Tanaka, Tatsuya Kanto, Michinori Kohara, Terumi Kamisawa, Kiminori Kimura – 19 July 2022 – Chronic cholestatic liver diseases are characterized by injury of the bile ducts and hepatocytes caused by accumulated bile acids (BAs) and inflammation. Wnt/β‐catenin signaling is implicated in organ fibrosis; however, its role in cholestatic liver fibrosis remains unclear.

Subscribe to